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ABSTRACT
Melanoma is a highly immunogenic tumor. Therefore, in recent years physicians have incorporated drugs
that alter the immune system into their therapeutic arsenal against this disease, revolutionizing in the
treatment of patients in an advanced stage of the disease. This has led us to explore and deepen our
knowledge of the immunology surrounding melanoma, in order to optimize its approach.
INTRODUCTION
At present, immunotherapy for metastatic melanoma is based on stimulating an individual’s own
immune system through the use of specific monoclonal antibodies. The use of immunotherapy
has meant that many of patients with melanoma have survived and therefore it constitutes a
present and future treatment in this field [1 -5].
At the same time, drugs have been developed targeting specific mutations, specifically BRAF,
resulting in large responses in tumor regression (set up in this clinical study to 18 months), as
well as a higher percentage of long-term survivors [6-9]. These large responses trigger the
massive antigens that are needed to reignite a state of immunocompetence in the patient, as
well as activating biomarkers that can guide response prediction.
Unfortunately, the recent interest in developing drugs against melanoma has not been
accompanied by the identification of biomarkers that are predictive of response or toxicity to
them. Although preliminary data determined immunohistochemistry was useful in the tumor
expression of the PDL-1 protein, subsequent work has failed to validate this predictive biomarker
or prognosis. In fact, one of the main problems of the study of the immune system is its
plasticity and adaptive nature. Tumor infiltrating lymphocytes (TIL), another possible postulated
and non-predictive marker validated, PDL-1 expression can be varied in short time frames
and this expression changes when biopsies are performed serially over time on the same
tumor [10]. Therefore, more biomarkers are needed to optimize the sequences of treatments
against melanoma. For these reasons, our work aims to combine both concepts: the use of
therapy directed against the BRAF mutation and the reactivation of acquired immunity against
melanoma.
It would therefore be useful to look for these changes in blood biomarkers in relation to
immunological mechanisms, to identify predictive markers of response to new treatments, in
order to identify long-term survivors with targeted therapy. Unfortunately many of these patients
will not benefit from these medicines, as they are difficult to fund in terms of human and economic
expenditure. However, this project seems to us to be an essential first step and the finding of
these biomarkers is yet to be explored.
The analysis of the gene expression changes and their correlation with clinical changes
can be developed using the tools provided by those companies which currently provide gene
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expression platforms. The gene expression platform used in this clinical study is NanoString,
which provides nCounter. However, nCounter has some limitations as the type of analysis is
restricted to a predefined set, and the introduction of clinical features is a complex task. This
paper presents an approach to collect the clinical information using a structured database and a
Web user interface to introduce this information, including the results of the gene expression
measurements, to go a step further than the nCounter tool.
As part of this work, we present an initial analysis of changes in the gene expression of a
set of patients before and after targeted therapy. This analysis has been carried out using Big
Data technologies (Apache Spark [11]) with the final goal being to scale up to large numbers
of patients, even though this initial study has a limited number of enrolled patients (12 in the
first analysis). This is not a Big Data problem, but the underlaying study aims at targeting 20
patients per year just in Málaga, and this could be extended to be used to analyze the 3.600
patients diagnosed with melanoma per year. Besides, as the software has been developed to
be applicable to any gene panel, it could be applied in any study of other diseases.
METHODS
In this section we present the three main steps that have been developed in this project until
now: clinical data collection, gene expression data collection and gene expression data analysis.
In order to collect the required data, we have developed a structured database to store clinical
and genomic data. Figure 1 shows part of the database schema, where we have collected:
Minimum set of personal data (gender, date of birth, medical records, medication, diagnosis
date, metastasis diagnosis date, etc.); The response to the treatment; The cancer’s progress,
including the different visits to the hospital and the blood test values at each visit; The BRAF
mutation; Primary location of the cancer; The files associated with the gene expression analysis.
The clinical information is collected by the patient’s physician (previously registered and
accepted in the clinical assay by the project coordinator). Thus, the effort of collecting the data
is shared by all the physicians participating in the project.
The files obtained from the sequencing process are loaded by the biologist (previously
registered in the system). These files are obtained from the NanoString platform. The NanoString
platform can analyze 12 samples in each cartridge. As a result we obtain 12 RCC files with
the gene counts for each of the gene panels. Each file is associated with the gene expression
of a patient at a specified stage of treatment. These files are locally stored with a patient
code, in addition to being annotated with the patient code from the project database. Then, the
biologist uploads the files attached to the patient profile, indicating the date when the sample
was collected and analyzed.
We have used the Immune Profiling Panel NanostringTM (770 genes), as it has been
specifically designed for cancer projects where immune aspects are studied. This panel includes
24 different immune cell types, common checkpoint inhibitors, CT antigens, and genes, covering
both the adaptive and innate immune response.
Using the gene expression files, a set of analysis tools has been developed to discover
patterns in the change of the gene expression levels. However, these files need to be prepro-
cessed, as NanoString returns the flat counts of the gene expressions. The pre-processing is
done to normalize the counts according to a set of control measures. The normalization process
is described in https://www.nanostring.com/download_file/view/251/3779.This
process has four steps:
• Step 1. Calculate the average of the expression of each positive control in all the samples.
• Step 2. Calculate the average of the results from the previous step.
• Step 3. Calculate the relationship between specific average and global average to obtain
the lane-specific scaling factor of each sample.
• Step 4. Multiply the expression of the genes by the lane-specific scaling factor.
Using the normalized gene expression values, we have produced four different represen-
tations to help clinicians analyze the expression results. These visualizations are interactive
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Figure 1. Extract of the database
Web graphs that can be explored by filtering the genes to be explored (just selecting a portion
with the mouse). In all cases we have used only 5% of the genes with more variance in the
expression:
• Type I. Comparison of the samples for a single patient (patient evolution). The visualization
of the expression change in a patient enables the individual analysis of the patient data
with a high degree of detail.
• Type II. Comparison of the basal status of the patients (classification of the patients
depending on the initial expression profile). This visualization enables the analysis of the
gene expression profiles to allow users to analyze those patients with a specific pattern.
For example, a user could select those patients with certain genes with a lower expression
than the rest of the patients, to later explore the possible expression growth.
• Type III. Comparison of the second sample of the patients (classification of the patients
according to to their expression after the evolution). This visualization also allows compar-
isons of patients afters the treatment.
• Type IV. Comparison of the patients including both samples (profiling on the patient
evolution in the gene expression). This visualization type is the most complete one
provided by this tool. It enables the classification and visualization of differences between
patients in the evolution of the gene expression. In this case the patient samples are
ordered, first showing the initial sample of all the patients, and then the results for the
second sample.
RESULTS
Using the four types, a first analysis of the patient evolution has been completed. Figure 2 shows
the first results for the fourth type for the patients sequenced until now. These initial results
show how genes related to the immune system have been activated in most of the patients
as expected. However, in one of the cases (patient P1059) the effect is the opposite. A first
qualitative analysis relates this to a previous immune activation in the patient.
The technology used has shown the possibility to scale up to larger numbers of patients, but
it needs more testing. However, the development of these visualizations in a easy-to-use user
interface will help clinical researchers analyze this data, and will enable semi-automatic analysis,
taking clinical variables into consideration.
The analysis of another set of patients has been done, but they are not included as the
visualization of the data showed that they were incorrect data, and were being studied by
NanoString and the biologist working on the project to detect where the errors were produced.
Thus, the use of these visualizations has demonstrated their usefulness not only in the data
analysis, but also in detecting erroneous expression patterns that cannot be easily detected
from the raw data.
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Figure 2. Comparison of the gene expression changes in all the sequenced patients
CONCLUSIONS
This paper has presented the initial results from the analysis of gene expression of the NanoS-
tring platform using Big Data technologies. These results are promising, but larger scale tests
must be developed once new patients have been sequenced.
These gene expression data is being collected in a structured database, and a Web user
interface is being developed to enable clinical researchers to analyze these data as soon as
they available from the NanoString platform. This integrated environment additionally includes
clinical features and the evolution of the patients that are collected in the same database, so
there is also work to be done in a combined analysis with the gene expression.
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